
|Articles|August 3, 2011
Allergan to buy Pa.-based Vicept
Allergan will pay as much as $275 million to acquire Vicept Therapeutics, the Orange County (Calif.) Business Journal reports.
Advertisement
Irvine, Calif. - Allergan, based here, will pay as much as $275 million to acquire Vicept Therapeutics, the Orange County (Calif.) Business Journal reports.
Allergan will pay $75 million for the company, based in Malvern, Pa., and up to $200 million in future milestone payments. Vicept’s V-101, a cream for treating redness associated with rosacea, is in mid-stage clinical trials. Vicept has two other products in the early stages of development.
An Allergan spokesman said the acquisition enhances the company’s dermatology research and development pipeline.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
KT-621 in Atopic Dermatitis: What Early EASI and Pruritus Data Show
2
Dermatology Times Spot Test: June 14, 2026
3
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
4
Digital Twins in Dermatology: Your Patient’s Virtual Double Is Coming
5














